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Abstract: Focal adhesion kinase (FAK) and steroid receptor coactivator (Src) are intracellular 
(nonreceptor) tyrosine kinases that physically and functionally interact to promote a variety of 
cellular responses. Plenty of reports have already suggested an additional central role for this 
complex in cancer through its ability to promote proliferation and anoikis resistance in tumor 
cells. An important role for the FAK/Src complex in tumor angiogenesis has also been established. 
Furthermore, FAK and Src have been associated with solid tumor metastasis through their 
ability to promote the epithelial mesenchymal transition. In fact, a strong correlation between 
increased FAK/Src expression/phosphorylation and the invasive phenotype in human tumors has 
been found. Additionally, an association for FAK/Src with resistances to the current anticancer 
therapies has already been established. Currently, novel anticancer agents that target FAK or 
Src are under development in a broad variety of solid tumors. In this article we will review the 
normal cellular functions of the FAK/Src complex as an effector of integrin and/or tyrosine kinase 
receptor signaling. We will also collect data about their role in cancer and we will summarize the 
most recent data from the FAK and Src inhibitors under clinical and preclinical development. 
Furthermore, the association of both these proteins with chemotherapy and hormonal therapy 
resistances, as a rationale for new combined therapeutic approaches with these novel agents, to 
abrogate treatment associated resistances, will also be reviewed.
Keywords: SRC, FAK, cancer, therapeutic target, FAK inhibitors, SRC inhibitors
The nonreceptor tyrosine kinases FAK and SRC
The FAK-SRC complex in the integrin  
and tyrosine kinase receptor setting
Integrins are a family of transmembrane receptors that link the extracellular matrix 
(ECM) and the intracellular actin-cytoskeleton. These cell-matrix areas of adhesion are 
known as focal adhesion (FA) contacts/areas. Integrins cluster when they bind to ECM. 
Integrin clustering has a structural role but also induces the activation of intracellular 
signaling pathways that lead to important cellular responses such as proliferation, 
survival, migration and invasion in both normal and tumor cells.1 In this setting, the 
linked activities of two nonreceptor intracellular tyrosine kinases, focal adhesion kinase 
(FAK) and steroid receptor coactivator (Src), is a common intracellular point of con-
vergence in the signaling initiated by this integrin-ECM interaction. In response to the 
clustering, FAK associates to the cytoplasmic tail of the integrin and in response to this 
association FAK phosphorylates at its tyrosine residue 397 (Y397). Although this Y397 
phosphorylation is mainly due to autophosphorylation; transphosphorylation by growth 
factors might also occur. This phosphorylated tyrosine provides a docking site for Src 
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(Figure 1).2 The tyrosine kinase Src, then, phosphorylates 
additional sites on FAK, leading to further increased activity 
of FAK and allowing the recruitment of proteins that contain 
Src homology 2 (SH2) domains such as Grb2 and PI3K.3 
The mutually activated FAK/Src complex then initiates a 
cascade of phosphorylation events of new protein–protein 
interactions to trigger several signaling pathways that 
eventually leads to different cellular responses. For instance, 
Grb2, once bound to FAK can recruit SOS into the complex 
and activates the downstream Ras-MAPK pathway and/or 
may also transduces the signal through the activation of the 
PI3K-Akt cascade.3–5
Adhesion is a hallmark of solid cancer cells and integrins 
are a nexus between intracellular signaling and cytoskeletal 
dynamics; besides, integrin-mediated signaling also intersects 
with growth factor-mediated signaling through various levels 
of cross-talk. In this complex network, the FAK/Src complex 
also transduces signals from tyrosine kinase receptors (TKRs) 
or integrates signals from both, integrins and TKRs, (see 
Figure 1) in normal and tumor cells.3,4 As an illustration of 
this connection in breast cancer, transforming growth factor 
β (TGF-β) has recently been found to be able to induce 
membrane-proximal clustering of human EGF (Epidermal 
Growth Factor) receptor 2, (HER2) and integrins by activating 
Src-FAK and receptor association to the cytoskeleton.6
Platelet-derived growth factor receptor (PDGF-R), 
epidermal growth factor receptor (EGF-R), f ibroblast 
growth factor receptor (FGF-R), insulin-like growth factor-
1 receptor (IGF-1R), hepatocyte growth factor (HGF-R), 
colony-stimulating factor-1 receptor (CSF-1R) or, stem cell 
factor receptor (SCF-R) are also TKRs that may transduce 
their signal by FAK/Src activation. As a consequence, the 
FAK/Src complex is potentially involved in different steps of 
tumorogenesis and further growth and metastatic progression 
of malignant tumors.7,8
The increased expression or activity of FAK and/or Src 
in tumors is associated with a more invasive and aggres-
sive phenotype and has lead to the development of Src and 
FAK inhibitors as new anticancer drugs.9–12 These drugs are 
able to block proliferation, survival, angiogenesis and/or 
migration/invasion in preclinical tumor models13 and some 
of them have already shown preliminary antitumor activity 
in clinical trials with cancer patients.14–19
FAK and Src structure
c-Src was the first characterized human oncogene. In 1909 
Peyton Rous identified the Rous Sarcoma’s Virus (RSV).20,21 
Later, in 1958, the v-Src gene was identified as the cause 
that allowed RSV to produce the sarcoma when the virus 
infected healthy chickens. The v-Src gene was taken up 
by RSV and incorporated into its genome conferring the 
virus the advantage of being able to stimulate uncontrolled 
proliferation in host chicken cells. Finally the human 
homologue of the v-Src gene, c-Src, was characterized as 
the first oncogene in humans.22
c-Src is a nonreceptor tyrosine kinase. The Src family 
comprises of eight members in humans (Src, Fyn, Yes, Lyn, 
Lck, Hck, Blk and Fgr) with a molecular weight between 
52–62 KDa.22,23 Each Src kinase family member is comprised 
of six domains. A SH4 domain placed at the N-terminal tail is 
involved in targeting Src to the plasmatic membrane. Adjacent 
to the SH4 domain, a region that is specific to each Src fam-
ily member followed by a SH3 and a SH2 domain, both of 
them involved in the interaction of Src with other intracellular 
proteins (Figure 2).23 Additionally, in the C-terminal tail, there 
is an SH1 domain involved in adenosine tri-phosphate (ATP) 
and substrate binding. This SH1 domain shows tyrosine kinase 
activity. The phosphorylation in the Y419 residue of the SH1 
domain is required for maximum kinase activity. Immediately 
adjacent to the SH1 domain, there is another C-terminal 
region that acts as a negative regulatory domain that is itself 
regulated by phosphorylation. After phosphorylation of the 
Y530 residue, placed in this negative regulatory domain, Src 
undergoes conformational changes and becomes inactive.23 
Src activation is regulated at many different levels. In response 
to a signal stimuli Src translocates from the cytosol to the 
membrane where it will be activated by phosphorylation, the 
intracellular localization of Src is therefore one of the key 
regulatory mechanisms that control Src activation.24 In addi-
tion the binding of FAK to the SH2 domain of Src relieves 
its autoinhibitory interaction that leads to the activation of 
Src. Once activated, Src phosphorylates FAK on a number 
of additional tyrosine residues, leading to further increased 
activity of FAK.2,23,25 In this sense, FAK acts as a molecular 
scaffold protein to activate and recruit Src to its substrates.
FAK was first identified in the search for proteins that 
where tyrosine phosphorylated in an integrin dependent 
manner and also in Src transformed fibroblasts as a key 
substrate of Src oncoprotein.26 It was described as a focal 
adhesion-associated nonreceptor protein tyrosine kinase27,28 
ubiquitously expressed and encoded by an evolutionarily 
highly conserved gene.
FAK harbors a central region with kinase activity that 
is flanked by a large N-terminal region that contains the 
erythrocyte band four 1-ezrin-radixin-moesin (FERM) domain 
and by a C-terminal region that contains the focal adhesion 
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Figure 1 FAK/Src complex mediated signaling pathway. 
Notes: The FAK/Src complex transduces signals from a variety of membrane receptors such as tyrosine kinase repectors and integrins through the activation of intracellular 
signaling pathways such as PI3K-AKt and Ras-MAPK to reach a cellular response. 
Abbreviations: ERK, extracellular signal regulated kinase; FA, focal adhesions; MEK, mitogen-activated protein; FAK, focal adhesion kinase; VEGF, vascular endothelial growth 
factor; MMPs, matrix metalloproteinases.
targeting (FAT) domain. The Y397 residue, immediately adja-
cent to the kinase domain, is autophosphorylated in response 
to the clustering of integrins. This autophosphorylation 
increases the catalytic activity of FAK and creates a high 
affinity binding site for the SH2 domain of Src. This 
interaction recruits and activates Src. The formation of the 
complex with Src is the most critical event in FAK-associated 
signaling. Src binds the Y397 residue and phosphorylates 
other FAK residues including Y576 and Y577 placed on the 
catalytic loop of the kinase and Y861 that are important for 
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full catalytic activity of FAK. Y925 has been also identi-
fied as an important site for phosphorylation by Src, which 
involves Src in induced epithelial mesenchymal transitions 
(EMTs).29,30 In the absence of stimuli from integrins and/or 
TKRs, the FERM domain works as a negative regulator of 
FAK activity. This domain interacts with the kinase domain 
preventing Y397 phosphorylation. Conversely, in response 
to co-clusters of integrins and TKRs, the FERM domain 
interacts with the cytoplasmic tail of the integrin allowing 
FAK-autophosphorylation in this Y397 residue. The FAT 
domain, placed in the C-terminal region, mediates the co-
localization of FAK with the FA areas through the interaction 
of FAK with the FA associated proteins talin and paxillin. 
Furthermore, two proline rich domains, placed adjacent to 
the FAT domain, mediate the interaction of FAK with SH3 
containing proteins such as p130CAS.9,11 The ability of FAK 
to promote the activation of p130CAS depends on Src activ-
ity. Although the scaffold function of FAK to recruit Src to 
its substrates is has already been well established, however 
less is known regarding FAK kinase activity.
Besides integrins, the N-terminal region of FAK also 
interacts with TKRs, and this interaction may be involved in 
the regulation of FAK activity and in addition in cross-talks 
between integrins and TKRs.31 Phosphorylation of FAK.
Y861 promotes association of FAK with the α
y
β
5
 integ-
rin following vascular endothelial growth factor (VEGF) 
stimulation.32
Different FAK isoforms from alternative splicing have 
been found: FAK, proline rich tyrosine kinase 2 (PYK2) and 
FAK related nonkinase (FRNK).9 FRNK lacks the catalytic 
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Figure 2 FAK and Src structure.
Notes: A) FAK structure. FAK harbors a central region with kinase activity that is flanked by a N-terminal region that contains the FERM domain and by a C-terminal region 
that contains the FAT domain. The autophosphorylation in its Y397 residue increases its catalytic kinase activity and allows the binding of specific intracellular proteins. FAK 
is phosphorylated by Src in its Y576 and Y577 residues allowing its full catalytic activity. In absence of stimulus, the FERM domain works as a negative regulator of FAK activity 
through its interaction with the kinase domain preventing the phosphorylation in Y397. In response of stimuli, the FERM domain interacts with the cytoplasmic tail of the 
integrins. Allowing the autophosphorylation of FAK in this tyrosine. The FAT domain, placed in the C-terminal region, mediates the co-localization of FAK with the FA areas 
through the interaction of FAK with the FA associated proteins talin and paxillin. Two proline-rich domains (PR) mediate the interaction of FAK with SH3 containing proteins 
such as p130 CAS. B) Src structure. Src is comprised of six domains: a SH4 involved in targeting Src to the plasmatic membrane, a region U that is specific of each Src family 
member, a SH3 and a SH2 domain involved in the interaction of Src with other intracellular proteins and a SH1 domain involved in ATP and substrate binding. The phosphorylation 
in Y419 residue of the SH1 domain is required for maximum kinase activity. Placed immediately adjacent to the SH1 domain there is a negative regulatory domain. After 
 phosphorylation of the Y530 residue, in the negative regulatory domain, Src becomes inactive.
Abbreviations: FAK, focal adhesion protein; RTK, tyrosine kinase receptor; FERM, Band 4.1 Ezrin, Radixin, Moesin; PI3K, phosphoinositide 3 kinase.
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domain working as a FAK inhibitor competing with nontrun-
cated endogenous FAK for the localization at FA areas.33
FAK activity is under strict regulation by a variety of 
kinases and phosphatases such as glycogen synthetase kinase 
3 type β (GSK3 β), tyrosine phosphatase SHP-2, serine/
threonine protein phosphatase type 1 as well as by Src.9,34,35
FAK and Src and their function  
in normal and tumor cells
Although, most available articles in the literature show 
FAK and Src as independent proteins, the current idea that 
both proteins work as a protein complex in the cellular 
signaling networks is emerging. FAK would form a binary 
complex with Src family kinases which can phosphorylate 
other substrates and trigger multiple intracellular signaling 
pathways that would induce different cellular responses.
FAK and Src are not only critical modulators of signaling 
pathways mediated by TKRs and integrins, they also respond 
to stimuli from G protein-coupled receptors, cell–cell 
adhesion proteins (ie, cadherins) and steroid hormone 
receptors to control a variety of normal and oncogenic 
cellular responses such as cell survival, proliferation and 
migration/invasion.4,22,23,34,36,37
FAK-null embryos exhibit an early embryonic lethal 
phenotype.38 These embryos show multiple defects, including 
a disorganized cardiovascular system due to extensive defects 
in angiogenesis and vasculogenesis.38 Accordingly, over 
expression of FAK in vascular endothelial cells promotes 
angiogenesis.39 In addition, conditional deletion of FAK 
in adult mouse epithelium was not lethal, and probably 
due to a functional compensatory effect mediated by its 
related family member PYK2.40 Although PYK2 knock out 
mice develop normally except they do exhibit defective 
macrophage migration.41,42 The above data suggested that 
endothelial cells may posses an adaptive capacity to switch 
to PYK2 dependant signaling after deletion or inhibition 
of FAK. Thus, FAK and PYK2 inhibition may result in an 
antiangiogenic effect.
An interesting interaction has also been reported between 
FAK and the tumor suppressor protein p53, via the FERM 
domain that triggers p53 degradation, so that loss of FAK 
results in activation of p53 which could eventually suggest new 
approaches to trigger cytotoxic drug induced apoptosis.43
Although, Src-null mice were viable, the analysis of 
homozygous mutants showed that they were deficient in 
bone remodeling (they had an impaired osteoclast function) 
and also developed osteopetrosis. This phenotype demon-
strated that Src is not required for general cell viability 
possibly due to a Src functional overlap with other related 
tyrosine kinases such as FAK. Therefore, Src may play 
an essential role in bone formation.44 Accordingly, cancer 
patients treated with a Src inhibitor showed reduced serum 
levels of bone resorption markers suggesting Src inhibi-
tors as a possible effective treatment for established bone 
metastasis.45,46
In normal adult tissues and tumor cells, FAK and Src 
control many important biological processes within the cell. 
They have been associated with responses of cell growth 
and survival.9,10 In addition, they have also been involved 
in anoikis (apoptosis induced when anchorage-dependent 
cells detach from the surrounding ECM) resistance in 
tumor cells.47–50 Hence, FAK/Src activation may promote 
the anchorage-independent growth/transformation of tumor 
cells through the inhibition of the apoptotic response.48,49 
FAK activation, in response to integrins, has an important 
role in FA turnover/rearrangement. This process is crucial 
for cell spreading and migration in physiological and 
pathological processes (ie, FA turnover is essential for 
EMTs during the metastatic behavior of tumor cells and 
in endothelial cell migration during tumor angiogenesis).9 
Phosphorylation of FAK-Y925 is the major Src-specific 
phosphorylation event that is associated with integrin 
adhesion dynamics and E-cadherin deregulation during 
Src-induced EMT.29,30
Furthermore, FAK has already been found, at elevated 
levels, in the majority of human cancers (head and neck, 
colon, breast, prostate, liver, thyroid, and others), particularly 
in highly invasive metastases.51 High levels of Phospho-FAK 
Y397 has already been found in: ovarian invasive tumors;52 
acute myeloid leukemia;53 squamous cell carcinoma of the 
laryn;54 invasive cervical carcinoma;55 invasive human colon 
cancer cells;56 medullary thyroid cancer cell lines;57,58 human 
pancreatic cancer cells;59 glioma cells;60 and other tumor 
types. Furthermore, high levels of FAK phosphorylated in 
other tyrosine residues have already been found in specific 
tumor types. Papillary thyroid cancer samples show high phos-
phor-Y861-FAK levels and high levels of phopho-Y861-FAK 
have also been correlated with sensitivity to the Src inhibitor 
AZD0530 in papillary and also in anaplastic thyroid cancer 
models.61 Although, the relationship between Src and cancer 
progression is best documented in colon and breast cancer.10,62 
Src over expression or over activation has also been shown in 
a variety of human biopsies from primary tumors and their 
metastases (Figure 3).23
An additional pro-angiogenic role for FAK and Src 
signaling in tumors has also been suggested.63–69 FAK 
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expression has been found in tumor endothelial cells 
from grade III and IV astrocytoma biopsies; whereas FAK 
expression was absent in endothelial cells of normal brain 
biopsies.63 Accordingly, tumor endothelial cells transfected 
with FRNK (a negative FAK regulator) showed less 
migration in vitro than control cells; suggesting that FAK is 
involved in tumor-angiogenesis, at least in part, through the 
induction of endothelial cell migration.63 Preclinical data 
from prostate cancer cell lines have also suggested a role 
for FAK signaling in the induction of VEGF expression 
in tumor cells.70 Additionally, an intracellular cross-talk 
between the Ang-1 TKR (Tie-2) involved in angiogenesis 
in tumors and integrin pathways has also been shown.71 
The binding of integrin α1β5 to ECM-glycoproteins may 
lead to the association of Tie-2 with integrin α1β. The 
stimulation of Tie-2 by Ang-1 may promote the recruitment 
of FAK to the TKR-integrin areas inducing an endothelial 
cell response (sprouting and stabilization of the new tumor 
vessels).71 Src has also been associated with VEGF pro-
duction in tumor cells.66 In fact, Src inhibition decreases 
angiogenesis in vivo.68,69
Immunohistological data about the expression/correla-
tion between active FAK/Src on primary tumors and on their 
metastases is still awaited, to explore the value of FAK/Src 
as predictors of tumor outcome.
In fact, as we will review below, a link for FAK/Src 
with chemoresistance has already been reported in tumor 
models. In fact, FAK downregulation enhances docetaxel 
cytotoxicity in ovarian cancer cells.72 Moreover, FAK 
downregulation also increases gemcitabine chemosensi-
tivity in pancreatic cancer cells.73 Accordingly, a variety 
of reports show a role for Src in the promotion of chemo-
resistance.74–77 Src inhibitors have already shown single 
agent activity in cancer patients after their progression to 
chemotherapy.78 Src inhibition promotes chemosensitivity 
in pancreatic cancer cells.74 In addition, a combination of 
5-fluorouracil (5-FU) and a Src inhibitor in 5-FU-resistant 
human pancreatic cancer cell lines restored 5-FU-induced 
apoptosis.74 The potential mechanism for 5-FU chemosen-
sitivity induced by Src inhibitors might be associated with 
the inhibition of the epidermal growth factor receptor-AKT 
(EGFR–AKT) pro-survival pathway induced by 5-FU. Fur-
Carcinoma in situ
ECM
Normal epithelium Dysplasia/Adenoma
Basement membrane
Invasive
carcinoma
EMT
Solid tumor progresion
overexpression/overactivation
Local invasion
FAK and Src 
Figure 3 Role of the FAK-Src complex in the malignant progression of solid tumors.
Notes: FAK and Src play a critical role in solid tumor progression mainly through its ability to promote the epithelial-mesenchymal transition associated with the metastatic 
behavior of solid tumors.
Abbreviations: ECM, extracellular matrix; EMT, epithelial mesenchynal transitions; FAK, focal adhesion kinase; Src, steroid receptor coactivator.
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thermore, a role for Src in mediating acquired endocrine 
resistance is also well established.10
Other FAK family members have also been associated 
with cancer. In fact, Pyk2 also shows a high expression 
and an association with tumor progression in a variety of 
tumor types such as: astrocytomas; breast; glioma; prostate; 
hepatocarcinoma; and nonsmall cell lung cancer.79–83 In 
addition, other Src family members have also been associated 
with solid and hematological tumors; and inhibitors against 
Src family members are under development as new anticancer 
drugs.84
FAK-Src and tumor associated 
epithelial mesenchymal transition
Epithelial mesenchymal transition (EMT) is a complex of 
cellular and molecular processes by which epithelial cells 
acquire mesenchymal and migratory properties.85 EMT takes 
place during critical phases of embryonic development and 
is also a crucial step in the infiltration and progression in 
solid tumors. Hallmarks of EMT include loss of cell–cell 
contacts, induction of FA turnover and increased expression 
of mesenchymal (f ibronectin, vimentin, N-cadherin, 
α-smooth muscle actin, and others) and invasiveness 
(ie, metalloproteinases) markers.86 The EMT is at the 
convergence of different molecular pathways involving cell 
survival and resistance to apoptosis, invasion and tumor 
angiogenesis, metastasis and drug resistance in advanced 
tumors.87
A critical molecular feature in the loss of cell–cell 
contacts during EMT is the downregulation of the adhesion 
molecule E-cadherin (delocalization/loss of E-cadherin 
expression). A variety of membrane receptors such as 
integrins, TKRs, serine-threonine kinase receptors are able 
to induce E-cadherin downregulation during development 
and tumor progression through the activation of specific 
intracellular signaling cascades such as Ras-MAPK and 
PI3K-Akt-mTOR. In fact, transcriptional repressors 
(Snail, Slug, Twist, or ZEB1/2) involved in EMTs during 
development are also induced in response to EMT stimuli 
to repress E-cadherin expression during tumor progres-
sion.86 Plenty of evidence suggests that FAK and Src, 
through its ability to integrate signals from numerous sig-
naling receptors, plays a critical role in tumor-associated 
EMTs promoting intracellular signaling pathways that 
lead to the induction of E-cadherin repressors and to the 
subsequent E-cadherin downregulation as well as that pro-
mote FA turnover to allow tumor cell migration/invasion 
(Figure 1B).88–91
New anticancer drugs that  
target FAK and Src
Based on evidence that supports FAK as a molecular scaffold 
protein, activated by Src to recruit its substrates; and that Src, as 
a tyrosine kinase is involved in the catalytic activation of FAK, 
and triggers FAK kinase activity to promote a variety of cellular 
responses during tumor progression, preclinical and clinical 
studies with new agents that employ different mechanisms for 
the blockade of FAK or Src kinases are currently underway.9,10 
We show below a summary of the most advanced FAK and 
Src inhibitors under development (see Table 1).
Historically the first drugs synthesized with the aim of 
inhibiting T-cell activation via the Src family kinases Lck and 
Fyn were PP1 and PP2. The latest one is very selective for 
Src family kinases (SFKs). After PD173955 and PD173956 
emerged with a lower selectivity than that of PP2, since these 
compounds were inhibitors of; Abl, Csk, platelet derived 
growth factor receptor (PDGFR) and EGFR. CGP76030 
and CGP77675 were also multi-targeted agents against 
SFKs, Abl, EGFR and VEGF receptor (VEGFR) and SFKs, 
EGFR, FAK, and VEGFR, respectively. A third generation of 
molecules characterized by their higher potency in enzyme 
assays and their dual inhibition of c-Abl in a variety of ima-
tinib-resistant c-Abl mutations appeared. The strong activity 
against c-Abl together with the potent anti-Src activity is 
explained by the strong structural similarity of the ATP bind-
ing domains in both kinases. The dual selectivity speeded up 
the development of these compounds.
At present, researchers are strongly focused on the 
study of the potential therapeutic benefits from the use of 
ATP-competitive kinase inhibitors against FAK and Src. 
These inhibitors interact with the ATP-binding pocket 
of FAK or Src and subsequently prevent FAK and Src 
autophosphorylation and therefore their activation.11
Dasatinib
Dasatinib (BMS-354825) is an orally active small multiselective 
inhibitor, which inhibits the kinases Src and Abl with IC50 val-
ues of 0.55 and 3.0 nM, respectively.92 Dasatinib also inhibits 
other Src family members such as Fyn (half maximal inhibitory 
concentration [IC50] of 0.2 nM), LcK (IC50 of 1.1 nM) and 
Yes (IC50 of 0.4 nM).92 Dasatinib blocks the wild type chimeric 
Bcr-Abl protein which arise from Philadelphia chromosome.93 
Dasatinib is a 20-fold more potent inhibitor than imatinib 
in cells expressing wild-type Bcr–Abl hybrid protein and it 
also has an antitumoral effect in those tumor cells express-
ing Bcr–Abl imatinib-resistant mutants.93 Dasatinib is also 
able to inhibit the tyrosine kinase receptors c-KIT, PDGFR-β 
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and ephrins (EPHA2).92 Dasatinib has already shown to have 
broad preclinical activity in solid and hematological tumor 
models.14,92 It has already been approved by the Food and Drug 
Administration (FDA) and by the European Medicines Agency 
(EMEA) for the second line treatment of imatinib-refractory 
chronic myelogenous leukemia (CML) and Philadelphia 
chromosome-positive acute lymphoblastic leukemia (ALL).14 
Currently, phase I/II clinical trials with dasatinib as a single 
agent or in combination are underway in a variety of solid and 
hematological tumors, based on the capability of dasatinib for 
blocking the activity Src family members.94 Besides effective-
ness in hematologic malignancies, dasatinib can suppress 
tumor growth in human breast cancer, human prostate, colon, 
ovarian, and lung cancer lines.95–100
AZD0530
AZD0530 is another novel, orally administered, potent, 
and highly selective inhibitor of Src (IC50 value  4 nM), 
other Src family members like LcK and Yes (both with 
IC50 values  4 nM) and Abl as well.101 Preclinical activity 
has been shown in: skin; breast; prostate; and pancreatic 
tumor models101 as well as estrogen receptor-positive breast 
cancer models102 where the combination of AZD0530 with 
tamoxifen103 and aromatase inhibitors104 prevented hormonal 
therapy resistance. This combination also shows an additive 
effect of delaying the growth of breast cancer cells.105
A variety of phase I and II clinical trials are currently 
underway with AZD0530 in monotherapy or in combina-
tion, in patients with solid tumors based on its capability to 
inhibit Src.106 Another possible use of AZD0530 has been 
recently reported. Based upon the hypothesis that Src could 
be involved in the development of metastases in xenograft 
modes where the growth of the primary tumor was controlled 
by radiation; this report shows that those tumors from mice 
receiving AZD0530 regress more quickly following radio-
therapy than their control counterparts.107
Bosutinib 
Bosutinib (SKI-606) is a potent, orally administered, 
bioavailable, dual Src (IC50 value of 3.8 nM) and Abl inhibitor 
which has already shown to have an antitumoral effect in 
chronic myelocytic leukemia (CML), colon, prostate and 
breast cancer models.108,109 Preclinical breast cancer models 
showed a decrease in in vitro cell motility and invasion and 
in vivo metastases after bosutinib treatment.110 A phase I 
clinical trial with bosutinib has been published showing; drug-
related dose-limiting toxicity of grade 3 diarrhea and grade 
3 rash (1 pt) with 400 mg being selected as the maximum 
tolerated dose.111 Currently, phase II, proof of concept clinical 
trials, in patients with CML who had failed to improve with 
Imatinib, and in patients with solid tumors, are underway.112
PF-562,271
PF-562,271 is a potent ATP-competitive, small molecule 
inhibitor of both FAK and the related kinase Pyk2 (IC50 values 
of 1.5 nM (0.7 ng/mL) and 14 nM (7 ng/mL), respectively). 
Table 1 Summary of FAK and Src inhibitors under clinical and preclinical development
Drug Target  
(IC50)
IC50 IC50 IC50 Preclinical activity Clinical activity
Src FAK Abl IGF1R
BMS-354825 
(Dasatinib)
0.55 nM 3.0 nM Solid and hematological  
tumor models
Approved in Imatinib  
 refractory CML and  
Philadelphia chromosome + ALL, 
Phase 1–2 clinical trials in  
solid and hematological tumors 
are underway
PF-562,271 797 nM 1.5 nM  
(0.7 ng/mL)
500 nM Colon, breast, prostate,  
pancreatic and lung tumor  
models
Phase 1 clinical trial in solid  
tumors has been already  
communicated
TAE-226 100 nM/L  
= 100 nM
300 nM/L  
= 300 nM
Glioma and human  
pancreatic tumor cell lines
Not yet
AZD0530 4 nM  
27 nM
Skin, prostate, breast  
and pancreatic tumor models
Phase 1–2 clinical trial  
underway
SKI-606  
(Bosutinib)
3.8 nM CML, colon and breast models Phase 1 clinical trial has been  
already communicated, Ph II 
 clinical trial in CML patients  
after imatinib failure under  
development
Abbreviations: FAK, focal adhesion kinase; CML, chronic myelogenous leukemia; IGF, insulin-like growth factor; IC, inhibitory concentration.
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PF-00562271 also inhibits other kinases such as c-Src and 
insulin growth factor 1 receptor (IGF1R) with less selectivity 
(IC50 value of 797 nM and IC50  500 nM respectively). 
This inhibitor has shown a broad preclinical activity.113 In 
PC3 human prostate tumor cells, PF-00562271 treatment 
blocks, anchorage independent tumor cell growth and tumor 
cell migration in vitro, has shown antitumoral effects in vivo.11 
PF-00562271 decreases FAK phosphorylation-status in vitro 
and shows antitumor efficacy in vivo, in xenografts from: 
human colon; breast; prostate; pancreatic; and hepatocellular 
carcinoma tumor cell lines.113–115 No weight loss, or increase in 
morbidity and mortality were observed in any in vivo experi-
ment and tumor growth inhibition was dose and drug exposure 
dependent. Furthermore, PF-562271 also showed an additional 
antiangiogenic effect over tumors.113 PF-562271 through the 
inhibition of FAK and PYK2 kinases may interfere with the 
ability of endothelial tumor cells to migrate, thus blocking 
the sprouting and stabilization of the new tumor vessels.63,116 
PF-00562271 treatment has also led to the blockade of the 
expression of pro-angiogenic growth factors in tumor cells, 
such as VEGF.70 Recently, Bagi and colleagues showed that 
PF-00562271 synergized with antiangiogenic agents that 
directly block VEGF signaling, through its ability to target 
different aspects of angiogenesis and tumor aggressiveness.115 
In addition, these authors show that the combination of these 
agents not only led to the blockade of tumor growth, it also 
impacted upon the ability of the tumor to recover on withdrawal 
of the therapy. PF-562,271 has also showed an in vivo effect 
in preventing the loss of bone, suggesting its potential activ-
ity in patients with bone metastases and cancer-associated 
osteoporosis.117 Therefore, PF-562,271 may comprise of a 
combined action over tumors: antiproliferative; proapoptotic; 
antiangiogenic; and antimetastatic action. Based on the 
preclinical data, a dose escalation phase 1 clinical trial with 
PF-562,271, administered orally as a single agent, in patients 
with solid tumors is currently underway. Tumor responses 
with PF-562,271 have been already reached in ovarian, colon 
together with head and neck cancer patients. Preliminary 
results showed a manageable safety profile with PF-562,271. 
In addition, continuous oral dosing is feasible and may be 
extended over 6 to 12 months in the majority of patients. The 
most common adverse events in the 32 evaluated patients with 
monitored safety data was: nausea in 14 patients (Grade 3); 
vomiting in 12 patients (only 1 patient with Grade 3); fatigue 
in 8 patients (Grade 3); and diarrhea in 6 patients (Grade 
3). Prolonged disease stabilization has already been observed 
in a variety of solid tumors. However, the maximum tolerated 
dose (MTD) and recommended Phase 2 dose have still to be 
published.15,16 In addition to PF 573,228, a closely related, early 
prototype FAK inhibitor118 has been reported to have appealing 
activity in combating ovarian cancer metastases,119,120 demon-
strating the growing body of evidence that supporting research 
of Src/FAK inhibitors in epithelial carcinoma.
TAE 226
TAE 226 is a low molecular weight, ATP-competitive tyro-
sine kinase inhibitor of FAK and IGF1R with an IC50 range 
of 100 to 300 nM/L.121 TAE 226 is still under preclinical 
development. Flow cytometry analysis of human glioma cell 
lines under TAE 226 treatment have shown an increase in 
the apoptotic and G0 (quiescent/nonproliferative) fractions 
after treatment, when these cells were compared with control/
nontreated cells.60 TAE 226 induced-apoptosis in the glioma 
tumor model is mediated by caspases and is correlated with 
the p53 status. In fact, apoptosis was only induced in the subset 
of glioma cell lines containing the mutant p53 gene.60
Additionally, TAE 226 treatment also prevented the in vitro 
attachment of these glioma cell lines. Furthermore, an in vivo 
intracranial glioma xenograft model showed a significantly 
higher median survival in the group of mice treated with 
TAE 226, at concentrations of 50–75 mg/kg. The treatment of 
ovarian cancer cell lines with TAE 226 inhibited cell growth 
in both a time- and dose-dependent manner; and enhanced 
docetaxel-mediated growth inhibition by 10 and 20 fold in the 
taxane-sensitive and taxane-resistant ovarian cell lines, respec-
tively. In addition, TAE 226 alone and in combination with 
chemotherapy significantly prolonged survival in tumor-bearing 
mice. The efficacy of TAE 226 was related to: reduced peri-
cyte coverage; the induction of apoptosis of tumor-associated 
endothelial cells; reduced microvessel density and tumor cell 
proliferation.121 TAE 226 also displayed an antitumoral effect 
in human pancreatic cell lines,122 esophageal cancer cell lines 
and xenografts, by a potent inhibition of PI3K-AKT-mTOR cell 
survival signaling.123 Clinical trials with this new dual FAK-
IGF1R inhibitor are planned. Recently, interesting experiments 
have suggested that the FAK–IGF–1R interaction site could be 
targeted; the specific disruption of this protein–protein interac-
tion with another small molecule inhibitor (INT2-31) reinforces 
the potential novel role of this antineoplastic strategy.124
FAK/Src and chemotherapy 
resistance
As we mentioned above, an association between FAK 
activation and resistance to chemotherapy has been broadly 
reported in human tumor models.72,73,125–128 Accordingly, the 
combination of conventional chemotherapeutic drugs with 
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FAK-targeting agents apparently offers greater efficacy in 
preclinical models than chemotherapy as a single agent. 
Treatment with FAK antisense oligonucleotides significantly 
induced apoptosis in human glioblastoma cells associated 
with a decrease in FAK protein levels.129 The in vitro cytotoxic 
effect achieved with the anti-FAK agent in monotherapy 
was almost the same as those obtained with different 
chemotherapeutic regimens such as cisplatin, etoposide 
and nimustine hydrochloride.129 When FAK antisense 
oligonucleotides and chemotherapy were administered in 
combination the antitumoral effect was clearly additive.129 
Treatment of squamous cell carcinoma models with recom-
binant FRNK peptides combined with etoposide, paclitaxel 
or 5-FU also showed an additive antitumoral effect.127
The effect of combined chemotherapy and anti-FAK agents 
were also explored in human HCC cells in vitro.130 When TNF-
α plus cycloheximide was combined with FAK-antisense, an 
increase in the apoptotic index was observed.130 Additionally, 
FAK siRNA was also able to potentiate gemcitabine action 
in pancreatic cancer cells73 increasing the apoptotic index. 
The in vivo treatment with FAK siRNA, in combination with 
gemcitabine, induced in a statistically significant manner, a 
larger inhibition in the size of the tumors than gemcitabine 
in monotherapy.73 FAK siRNA incorporated in liposomes 
was administered to mice bearing tumors from human ovar-
ian cancer cells.131 Mice treated with siRNA-DOPC showed 
a decrease in tumor weight. Docetaxel in combination with 
siRNA-DOPC resulted in an even greater reduction in tumor 
weight.131 This combination also showed: antiangiogenic 
properties;131 it decreased microvessel density; VEGF and 
MMP-9 secretion; and increased apoptosis in tumor cells, in 
addition to tumor-associated endothelial cells.131 Treatment 
with siRNA-DOPC resulted in a decrease in the tumor weight 
of cisplatin-resistant xenografts as well.131 These data sug-
gest that the combination of anti-FAK agents with docetaxel 
or cisplatin may be a valuable therapeutic approach in the 
chemotherapy of resistant ovarian cancer. Smith and colleagues 
showed that FAK downregulation enhanced the effects of 5-FU 
in human melanoma cells.132 FAK antisense oligonucleotides 
significantly increased cell detachment and apoptosis when 
they were administered alone or in combination with 5 FU.132 
This led to the decrease in FAK protein levels, an effect that 
was also observed with the 5-FU alone. Accordingly, FAK 
blockade plus 5-FU showed and additive effect.
There are also, preclinical data supporting the role of 
Src in chemoresistance. The inhibition of Src reversed 
chemoresistance toward 5-FU in human pancreatic carcinoma 
cells.74 Furthermore, Src inhibition also impaired both inherent 
and acquired gemcitabine resistance in human pancreatic 
adenocarcinoma cells.75 The combination of dasatinib and 
chemotherapy (5′-5′-DFUR or cisplatin) was synergistic in 
triple-negative breast cancer cells.99 In addition, phase 1 clini-
cal trials are currently ongoing, with the Src inhibitor dasatinib 
in combination with chemotherapy in solid tumors.94,133
Interestingly the combination of paclitaxel/carbolatin 
standard chemotherapy in ovarian cancer has shown 
interesting synergism from this combined approach at the 
cell line level, that requires further investigation.134
In conclusion, current evidence shows that FAK/
Src-targeting compounds enhance the action of conventional 
anticancer agents at least in preclinical tumor models. 
Nonetheless, further molecular studies testing the activation 
status of both kinases in tumor biopsies and clinical trials, 
with anti-FAK/anti-Src agents and different chemotherapeutic 
schedules are still required to confirm if this complex is 
involved in treatment resistance and if the combination can 
enhance the efficacy of conventional chemotherapy in the 
clinical setting.
The interest of targeting FAK  
and Src in breast cancer
The Src/FAK signaling pathway is related to multiple receptor 
tyrosine kinases (RTKs) and intracellular mediators with a 
prominent role in the biology of the different subtypes of 
breast cancer.135
On one hand, c-Src interacts with and contributes to the 
signaling cascade of different RTKs; modulates their turnover 
by interfering in the endocytosis; and ubiquitination; in to 
taking part in the cytoskeleton rearrangement, migration and 
survival processes started at the RTKs’ level in tumor cells.7 
In breast cancer there is evidence of the interaction between 
c-Src and EGFR, (although short of a synergistic activity), 
connected to the crosstalk between estrogen receptor (ER) 
and EGFR.136,137 HER2 is coexpressed with c-Src in breast 
cancer138 and their interaction seems to facilitate the migratory 
and metastatic phenotype of these cells.139,140 Likewise, HER2 
is actually involved in c-Src regulation,140 another mechanism 
of activation of HER2 such as the transactivation through 
G-protein receptors (ie, CXCR4).141 C-Src has also been 
proposed to be involved in the modulation of HER2–HER3 
heterocomplexes in an intracellular mediated pattern.142
However, Src has also been linked to the endoplasmic 
reticulum (ER) nongenomic activity143 and the homeostasis 
of the ER144 in the tumor cells.
Src inhibitors have been developed in different breast 
cancer subtypes. Triple negative breast cancer has emerged 
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as a potential field to be explored by this family of drugs. 
Two independent groups have described genetic profiles 
associated with a response to dasatinib95,145 highlighting 
the particular sensitivity of the basal-like phenotype to 
this Src inhibitor. This molecular marker approach has led 
to a phase 2 trial in the clinical setting146 showing modest, 
although encouraging, results to be tested in further trials, 
in combination with chemotherapy.
Hormone receptor-positive breast cancer, resistant to the 
classic endocrine therapy strategies, has become another 
field actively studied. In the tamoxifen resistance setting, the 
upregulation of different RTKs’ signaling pathways has been 
involved. It has been suggested that the resistant phenotype 
is not just the result of an estrogen independent growth,147 
but is also linked to an alteration in the relationship between 
the cells and the extracellular matrix, so that these tumor 
cells acquire an invasive and migratory phenotype148,102 that 
favors tumor dissemination. It has been demonstrated that 
anti-HER2 therapies are able to eliminate the agonist effect 
of tamoxifen, restoring its antitumoral capacity149 and the 
blockade of both pathways, showing an increased efficacy 
against endocrine-resistant tumors.100,150,151
However, these combinations have not shown a definitive 
effect regarding the migratory and invasive phenotype,148 
moreover, the tumoral cells eventually develop double 
resistance that results in an even more invasive behavioral pat-
tern.102,152 This dual resistant phenotype is characterized by an 
increase Src kinase activity, that defines another opportunity 
to target endocrine resistant breast cancer. The in vitro utility 
of Src inhibitors; due to the Src/FAK relationship in the acqui-
sition of endocrine resistance in breast cancer, has already 
been tested.153–156 However, a recent article showed an oppo-
site role for Src in breast cancer. Campbell and colleagues 
analyzed 262 breast cancer specimens, before tamoxifen 
treatment, for active Src expression by tissue microarray. 
The authors showed that phosphorylated c-Src in the nucleus 
was significantly associated with improved patient outcome 
in ER-positive breast cancer.157 The current findings suggest 
a crosstalk between ER and Src/FAK kinases, so that the addi-
tion of agents that block Src and/or FAK to hormonal therapy 
may improve the efficacy of the current endocrine therapies 
(aromatase inhibitors and tamoxifen). Clinical trials in breast 
cancer patients with dasatinib and aromatase inhibitors are 
underway in breast cancer patients.94
Conclusions
As we reviewed above FAK and Src form a mutually 
activated complex that acts as a common intracellular point 
of convergence in the signaling initiated by a variety of 
membrane receptors (RTKs, Integrins, G-coupled recep-
tors, ER and others) to trigger a cascade of phosphorylation 
events and new protein–protein interactions in tumor cells 
and tumor endothelial cells, that allow the angiogenic and 
metastatic behavior of tumors. In fact, preclinical data 
with anti-Src and anti-FAK agents under development 
show that both types of inhibitors lead to antiproliferative, 
antiangiogenic and antimetastatic responses in human 
tumor models; a synergistic effect with other anticancer 
agents has been also observed. Therefore the inhibition 
of one of these kinases appears to be a successful thera-
peutic approach to avoid recurrence and dissemination of 
the primary tumor and also the progression of metastatic 
lesions.
Currently, we have robust data to believe FAK and c-Src 
inhibitors as a novel and promising anticancer strategy to 
combine with current anticancer therapies. A synergistic 
effect has already been shown when they are combined 
with other antitarget agents (ie, gefitinib, imatinib and 
 sunitinib). Furthermore, these drugs have also been shown 
to be good candidates in the avoidance of chemotherapy and 
 hormonotherapy resistances.
In addition, although it remains difficult to asses the 
efficacy of antimetastatic agents in the clinical setting, 
its appears that the inhibition of Src and FAK may have a 
potent anti-invasive effect, to delay tumor dissemination 
rather than real tumor shrinkage. Furthermore, although 
levels have already been seen as a possible predictor of 
response to Src inhibitors there is still a lack of suitable 
biomarkers that would be able to predict a response to these 
agents. In addition to current clinical studies of biomarker 
assays, the use of more sophisticated imaging technolo-
gies and the testing of the tumor, guided by biochemical 
rational, will help to maximize the development of these 
new compounds.
We have reviewed those trials with FAK and Src inhibitors 
under clinical development as a single agent or in combina-
tion with other therapeutic approaches. They have already 
shown clinical benefits in cancer patients with solid tumors. 
The identification of useful biomarkers to assess target inhi-
bition, anti-invasive efficacy and predict treatment response 
will be crucial for future clinical trials.
Acknowlegments
We would like to thank to Nieves Ruíz-Ayllón for the editorial 
assistance. The authors report no conflicts of interest relevant 
to this research.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
23
9.
10
8.
7 
on
 0
1-
O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2010:394
Bolós et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
References
 1. Guo W, Giaconti FG. Integrin signaling during tumor progression. Nat 
Rev Mol Cell Biol. 2004;5(10):816–826.
 2. Calalb MB, Polte TR, Hanks SK. Tyrosine of focal adhesion kinase at 
sites in the catalytic domain regulates kinase activity: a role for Src 
family kinases. Mol Cell Biol. 1995;15:954–963.
 3. Satyajit K Mitra, David D Schlaepfer. Integrin-regulated FAK–Src 
signaling in normal and cancer cells. Current Opinion in Cell Biology. 
2006;18(5):516–523.
 4. Bruton VG, MacPherson IRJ, Frame MC. Cell adhesion receptors, 
tyrosine kinases and actin modulators: a complex three-way circuitry. 
Biochim Biophys Acta. 2004;1692:121–144.
 5. Playford MP, Schaller MD. The interplay between Src and inte-
grins in normal and tumor biology. Oncogene. 2004;18;23(48): 
7928–7946.
 6. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. 
Transforming growth factor beta induces clustering of HER2 and 
integrins by activating Src-focal adhesion kinase and receptor 
association to the cytoskeleton. Cancer Res. 2009;69(2):475–478.
 7. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src 
family kinases and receptor tyrosine kinases. Oncogene.2004;23(48): 
7957–7968.
 8. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med. 
2008;359(26):2814–2823.
 9. Van Nimwegen MJ, Van Dewater B. Focal adhesion kinase: a potential 
target in cancer therapy. Biochem Pharmacol. 2007;73:597–609.
 10. Morgan L, Nicholson RI, Hiscox S. SRC as a therapeutic target 
in breast cancer. Endocr Metab Immune Disord Drug Targets. 
2008;8(4):273–278.
 11. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion 
kinase: targeting adhesion signaling pathways for therapeutic 
intervention. Clin Cancer Res. 2008;14(3):627–632.
 12. Finn RS. Targeting Src in breast cancer. Ann Oncol. 2008;19(8): 
1379–1386.
 13. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M. Cellular 
characterization of a novel focal adhesion kinase inhibitor. J Biological 
Chem. 2007;282(20):14845–14852.
 14. Jarkowski A, Sweeney RP. Nilotinib: a new tyrosine kinase inhibitor 
for the treatment of chronic myelogenous leukemia. Pharmacotherapy. 
2008;28(11):1374–1382.
 15. Siu LL, et al. Phase 1 study of a focal adhesion kinase (FAK) inhibitor 
PF-00562271 in patients (pts) with advanced solid tumors. Abstract 
3527. 2007 ASCO Annual Meeting. Chicago, IL, USA.
 16. Siu LL, et al. A phase I clinical, pharmacokinetic (PK) and 
pharmacodynamic (PD) evaluation of PF-00562271 targeting focal 
adhesion kinase (FAK) in patients (pts) with advanced solid tumors. 
Abstract 3534. 2008 ASCO Annual Meeting. Chicago, IL, USA.
 17. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel 
combination treatment for patients with castration-resistant progressive 
prostate cancer: A phase I/II study (CA180086). Abstract 5061. 2009 
ASCO Annual Meeting. Chicago, IL, USA.
 18. Kluger HM, Dudek A, McCann C, et al. A phase II trial of dasatinib 
inadvanced melanoma. Abstract 9010. 2009 ASCO Annual Meeting. 
Chicago, IL, USA.
 19. Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu 
amplified and ER/PR-positive breast cancer: Phase II study CA180088. 
Abstract 1011. 2009 ASCO Annual Meeting. Chicago, IL, USA.
 20. Rous PA. Transmission of a malignant new growth by means of a 
cell-free filtrate. JAMA. 1911;56:198–202.
 21. Rous PA. A sarcoma of the fowl transmissible by an agent separable 
from the tumor cells. J Exp Med. 1911;13(4):397–411.
 22. Steven Martin G. The hunting of the Src. Nature Rev Molec Cell Biol. 
2001;2:467–475.
 23. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6): 
470–480.
 24. Ingley E. Src family kinases: regulation of their activities, levels 
and identification of new pathways. Biochim Biophys Acta. 2008; 
1784(1):56–65.
 25. Cox BD, Natarajan M, Stettner MR, Gladson CL. New concepts 
regarding focal adhesion kinase promotion of cell migration and 
proliferation. J Cell Biochem. 2006;99(1):35–52.
 26. Kanner SB, et al. Monoclonal antibodies to individual tyrosine-
phosphorylated protein substrates of oncogene-encoded tyrosine 
kinases. Proc Natl Acad Sci. 1990:87(9):3328–3332.
 27. Shaller MD, Borgman CA, Cobb BS, et al. pp125FAK a structurally 
distinctive protein-tyrosine kinase associated with focal adhesions. Proc 
Natl Acad Sci. 1992;89:5192–5196.
 28. Schaller MD, Parsons JT: Focal adhesion kinase and associated proteins. 
Curr Opin Cell Biol. 1994;6:705–771.
 29. Brunton VG, Avizienyte E, Fincham VJ, et al. Identification of 
Src-specific phosphorylation site on focal adhesion kinase: dissection 
of the role of Src SH2 and catalytic functions and their consequences 
for tumor cell behavior. Cancer Res. 2005;65(4):1335–1342.
 30. Avizienyte E, Wyke AW, Jones RJ, et al. Src-induced de-regulation of 
E-cadherin in colon cancer cells requires integrin signaling. Nat Cell 
Biol. 2002;4(8):632–638.
 31. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin 
signals to promote cell migration. Nat Cell Biol. 2000;2(5):249–256.
 32. Eliceiri BP, Puente XS, Hood JD, et al. Src-mediated coupling of focal 
adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth 
factor signaling. J Cell Biol. 2002;157(1):149–160.
 33. Schaller MD, Borgman CA, Parsons JT. Autonomous expression of a 
noncatalytic domain of the focal adhesion associated protein tyrosine 
kinase pp.125FAK. Mol Cell Biol. 1993;13:785–791.
 34. Mitra SK, Schaepfer DD. Integrin-regulated FAK-C-src signaling in 
normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–523.
 35. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. 
Cancer Metastasis Rev. 2009;28(1–2):35–49.
 36. Parsons JT, Martin KH, Slack JK, Taylor JM. Focal adhesion kinase: a 
regulator of focal adhesion dynamics and cell movement. Oncogene. 
2000;19(49):5606–5613.
 37. Summy JM, Gallick GE. Src family kinases in tumor progression and 
metastasis. Cancer Metastasis Rev. 2003;22:337–358.
 38. Ilic D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced 
focal adhesion contact formation in cells from FAK-deficient mice. 
Nature 1995;377:539–544.
 39. Peng X, Ueda H, Zhou H, et al. Overexpression of focal adhesion kinase 
in vascular endothelial cells promotes angiogenesis in transgenic mice. 
Cardiovascular Res. 2004;64:421–430.
 40. Weis SM, Lim ST, Lutu-Fuga KM, et al. Compensatory role for Pyk2 
during angiogenesis in adult mice lacking endothelial cell. FAK. J Cell 
Biol. 2008;181:43–50.
 41. Guinamard R, Okigaki M, Schlessinger J, Ravetich JV. Absence of 
marginal zone B cell in Pyk2-deficient mice defines their role in the 
humoral response. Nat Immunol. 2000;1:31–36.
 42. Okigaki M, Davis C, Falasca M, et al. Pyk2 regulates multiple signaling 
events crucial for macrophage morphology and migration. Proc Nat 
Acad Sci. 2003;100:10740–10745.
 43. Lim ST, Chen XL, Lim Y, et al. Nuclear FAK promotes cell proliferation 
and survival through FERM-enhanced p53 degradation. Mol Cell. 
2008;29(1):9–22.
 44. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption 
of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 
1991;64(4):693–702.
 45. Roodman GD: Mechanisms of bone metastasis. N Engl J Med. 
2004;350:1655–1664.
 46. Rucci N, Susa M, Teti. Inhibition of protein kinase c-Src as a therapeutic 
approach for cancer and bone metastases. Anticancer Agents Med Chem. 
2008;8(3):342–349.
 47. Zhan M, Zhao H, Han ZC. Signaling mechanisms of anoikis. Histol 
Histopathol. 2004;19(3):973–983.
 48. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Focal adhesion 
kinase gene silencing promotes anoikis and suppresses metastasis of human 
pancreatic adenocarcinoma cells. Surgery. 2004;135(5):555–562.
 49. Liu G, Meng X, Jin Y, et al. Inhibitory role of focal adhesion kinase on 
anoikis in the lung cancer cell A549. Cell Biol Int. 2008;32(6):663–670.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
23
9.
10
8.
7 
on
 0
1-
O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2010:3 95
FAK-Src complex as a therapeutic target in cancerDovepress
submit your manuscript | www.dovepress.com
Dovepress 
 50. Díaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated 
anoikis resistance of human osteosarcoma cells requires Src activation. 
Eur J Cancer. 2006;42(10):1491–500.
 51. Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological 
processes important for the pathogenesis of cancer. Cancer Metastasis 
Rev. 2003;22(4):359–374.
 52. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. 
Differential expression of protease activated receptor 1 (Par1) and 
pY397FAK in benign and malignant human ovarian tissue samples. 
Int J Cancer. 2005;113(3):372–378.
 53. Recher C, Ysebaert L, Beyne-Rauzy O, et al. Expression of focal adhe-
sion kinase in acute myeloid leukemia is associated with enhanced 
blast migration, increased cellularity, and poor prognosis. Cancer Res. 
2004;64(9):3191–3197.
 54. Aronsohn MS, Brown HM, Hauptman G, Kornberg LJ. Expression 
of focal adhesion kinase and phosphorylated focal adhesion kinase in 
squamous cell carcinoma of the larynx. Aronsohn MS, Brown HM, 
Hauptman G, Kornberg LJ.
 55. Moon HS, Park WI, Choi EA, Chung HW, Kim SC. The expression and 
tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and 
focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol 
Cancer. 2003;13(5):640–646.
 56. Ding J, Li D, Wang X, Wang C, Wu T. Fibronectin promotes invasive-
ness and focal adhesion kinase tyrosine phosphorylation of human 
colon cancer cell. Hepatogastroenterology. 2008;55(88):2072–2076.
 57. Panta GR, Nwariaku F, Kim LT. RET signals through focal adhesion kinase 
in medullary thyroid cancer cells. Surgery. 2004;136(6):1212–1217.
 58. Panta GR, Du L, Nwariaku FE, Kim LT. Direct phosphorylation 
of proliferative and survival pathway proteins by RET. Surgery. 
2005;138(2):269–274.
 59. Tong Z, Kunnumakkara AB, Wang H, et al. Neutrophil gelatinase-
associated lipocalin: a novel suppressor of invasion and angiogenesis 
in pancreatic cancer. S Cancer Res. 2008;68(15):6100–6108.
 60. Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion 
kinase and insulin-like growth factor-I receptor kinase suppresses 
glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007;6(4): 
1357–1367.
 61. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen 
BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion 
kinase complex as a novel therapeutic target in papillary and anaplastic 
thyroid cancer. J Clin Endocrinol Metab. 2009;94(6):2199–2203.
 62. Chen J. Is Src the key to understanding metastasis and developing new 
treatments for colon cancer? Nat Clin Pract Gastroenterol Hepatol. 
2008;5(6):306–307.
 63. Haskell H, Natarajan M, Hecker TP, et al. Focal adhesion kinase is 
expressed in the angiogenic blood vessels of malignant astrocytic tumors 
in vivo and promotes capillary tube formation of brain microvascular 
endothelial cells. Clin Cancer Res. 2003;9(6):2157–2165.
 64. Angelucci A, Bologna M. Curr. Targeting vascular cell migration as a 
strategy for blocking angiogenesis: the central role of focal adhesion 
protein tyrosine kinase family. Pharm Des. 2007;13(21):2129–2145.
 65. Earley S, Plopper E. Disruption of focal adhesion kinase slows tran-
sendothelial migration of AU-565 breast cancer cells. Biochem Biophys 
Res Commun. 2006;350:405–412.
 66. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. 
Selective requirement for C-src kinases during VEGF-induced 
angiogenesis and vascular permeability. Mol Cell. 1999;4:915–924.
 67. Niu G, et al. Constitutive Stat3 activity up-regulates VEGF expression 
and tumor angiogenesis. Oncogene. 2002;21:2000–2008.
 68. Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases 
inhibits angiogenesis in vivo: implications for a mechanism involving 
organization of the actin cytoskeleton. Exp Cell Res. 2003;291: 
70–82.
 69. Laird AD, et al. Src family kinase activity is required for signal tranducer 
and activator of transcription 3 and focal adhesion kinase phosphoryla-
tion and vascular endothelial growth factor signaling in vivo and for 
anchorage-dependent and-independent growth of human tumor cells. 
Mol Cancer Ther. 2003;2:461–469.
 70. Sheta EA, Harding MA, Conaway MR, Theodorescu D. Focal adhesion 
kinase, Rap1, and transcriptional induction of vascular endothelial 
growth Factor. J Natl Cancer Inst. 2000;92(13):1065–1073.
 71. Cascone I, Napione L, Maniero F, Serini G, Bussolino FJ. Stable interaction 
between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates 
endothelial cell response to Ang-1. Cell Biol. 2005;170(6):993–1004.
 72. Halder J, Landen CN Jr, Lutgendorf SK, et al. Focal adhesion kinase 
silencing augments docetaxel-mediated apoptosis in ovarian cancer 
cells. Clin Cancer Res. 2005;11(24 Pt 1):8829–8836.
 73. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. 
RNA interference targeting focal adhesion kinase enhances pancreatic 
adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res 
Commun. 2003;311(3):786–792.
 74. Ischenko I, Camaj P, Seeliger H, et al. Inhibition of Src tyrosine kinase 
reverts chemoresistance toward 5-fluorouracil in human pancreatic 
carcinoma cells: an involvement of epidermal growth factor receptor 
signaling. Oncogene. 2008;27(57):7212–7222.
 75. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition 
of SRC tyrosine kinase impairs inherent and acquired gemcitabine 
resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 
2004;10(7):2307–2318.
 76. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. siRNA directed 
against c-Src enhances pancreatic adenocarcinoma cell gemcitabine 
chemosensitivity. J Am Coll Surg. 2004;198(6):953–959.
 77. Shah AN, Gallick GE. Src, chemoresistance and epithelial to 
mesenchymal transition: are they related? Anticancer Drugs. 
2007;18(4):371–375.
 78. Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu 
amplified and ER/PR-positive breast cancer: Phase II study CA180088; 
Abstract: 1011. 2009 ASCO Annual Meeting, Chicago IL, USA.
 79. Gutenberg A, Brück W, Buchfelder M, Ludwig HC. Expression of 
tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta 
Neuropathol. 2004;108(3):224–230.
 80. Behmoaram E, Bijian K, Jie S, et al. Focal adhesion kinase-related pro-
line-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed 
in early-stage and invasive ErbB-2-positive breast cancer and cooperate 
for breast cancer cell tumorigenesis and invasiveness. Am J Pathol. 
2008;173(5):1540–1550.
 81. Sun CK, Ng KT, Sun BS, et al. The significance of proline-rich tyrosine 
kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. 
Br J Cancer. 2007;97(1):50–57.
 82. Iiizumi M, Bandyopadhyay S, Pai SK, et al. RhoC promotes metastasis 
via activation of the Pyk2 pathway in prostate cancer. Cancer Res. 
2008;68(18):7613–7620.
 83. Zhang S, Qiu X, Gu Y, Wang E. Up-regulation of proline-rich tyrosine 
kinase 2 in non-small cell lung cancer. Lung Cancer. 2008;62(3): 
295–301.
 84. Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as 
molecular targets for cancer therapy. Anticancer Agents Med Chem. 
2007;7(6):651–659.
 85. Thiery JP. Epithelial-mesenchymal transitions in development and 
pathologies. Curr Opin Cell Biol. 2003;15(6):740–746.
 86. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype? Nat Rev 
Cancer. 2007;7(6):415–428.
 87. Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and 
therapeutic perspective of the epithelial-to-mesenchymal transitions 
in epithelial cancers. Drug Resist Updat. 2008;11(4–5):123–151.
 88. Bailey KM, Liu JJ. Caveolin-1 up-regulation during epithelial to 
mesenchymal transition is mediated by focal adhesion kinase. Biol 
Chem. 2008;283(20):13714–13724.
 89. Cicchini C, Laudadio I, Citarella F, et al. TGFbeta-induced EMT requires 
focal adhesion kinase (FAK) signaling. Exp Cell Res. 2008;314(1):143–
152.
 90. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal 
transition in head and neck squamous carcinoma: association of Src 
activation with E-cadherin down-regulation, vimentin expression, 
and aggressive tumor features. Cancer. 2008;112(9):2088–2100.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
23
9.
10
8.
7 
on
 0
1-
O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2010:396
Bolós et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
 91. Wei J, Xu G, Wu M, et al. Overexpression of vimentin contributes to 
prostate cancer invasion and metastasis via src regulation. Anticancer 
Res. 2008;28(1A):327–334.
 92. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-
6methylphneyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-
methylpyrimidin-4-ylamino)thiazole-5 carboxamide (BMS-354825),a 
dual Src/Abl. kinase inhibitor with potent antitumor activityin 
pre-clinical assays. J Med Chem. 2004; 47(27):6658–6661.
 93. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib 
(BMS-354825) bound to activated ABL kinase domain elucidates its 
inhibitory activity against imatinib-resistant ABL mutants. Cancer 
Res. 2006 1;66(11):5790–5797.
 94. Kopetz S, Shah AN, Gallick GE. Src continues aging: current 
and future clinical directions. Clin Cancer Res. 2007;13(24): 
7232–7236.
 95. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active 
small molecule inhibitor of both the src and abl kinases, selectively 
inhibits growth of basal-type/“triple-negative” breast cancer cell 
lines growing in vitro. Breast Cancer Res Treat. 2007;105(3): 
319–326.
 96. Huang F, Reeves K, Han X, et al. Identification of candidate molecular 
markers predicting sensitivity in solid tumors to dasatinib: rationale 
for patient selection. Cancer Res. 2007;67(5):2226–2238.
 97. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases 
inhibits growth and lymph node metastases of prostate cancer in an 
orthotopic nude mouse mode. Cancer Res. 2008;68(9):3323–3333.
 98. Xiao-Feng Le, Weiqun Mao, Zhen Lu, Robert C Bast Jr. Dasatinib 
induces autophagy as well as growth arrest in human ovarian cancer 
cells. Abstract 388. AACR 2009.
 99. Tryfonopoulos D, O’Donovan N, Corkery B, Clynes M, Crown J. 
Activity of dasatinib with chemotherapy in triple-negative breast cancer 
cells. Abstract: e14605. 2009 ASCO Annual Meeting, Chicago, IL, 
USA.
 100. Seoane S, Montero JC, Pandiella A, Ocana A. Effect of dasatinib 
on the activity of trastuzumab in HER2- overexpressing breast 
cancer cells; Abstract: 1084. 2009 ASCO Annual Meeting, Chicago, 
IL, USA.
 101. Hennequin LF, Allen J, Breed J, et al. N-(5-chloro-1,3-benzodioxol-
4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-
pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally 
available, dual-specific c-Src/Abl kinase inhibitor. Med Chem. 
2006;49(22):6465–6488.
 102. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. 
Elevated Src activity promotes cellular invasion and motility in 
tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 
2006;97:263–274.
 103. Hiscox S, Jordan NJ, Smith C, et al. Dual targeting of Src and ER 
prevent acquired antihormone resistance in breast cells. Breast Cancer 
Res Treat. 2009;115(1):57–67.
 104. Chen Y, Guggisberg N, Jorda M, et al. Combined Src and Aromatase 
Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass 
Pathways Are Activated in AZD0530-Resistant Tumors. Clin Cancer 
Res. 2009;15(10):3396–3405.
 105. Herynk MH, Beyer AR, Cui Y, et al. Cooperative action of 
tamoxifen and c-Src inhibition in preventing the growth of estrogen 
receptor-positive human breast cancer cells. Mol Cancer Ther. 2006 
5(12):3023–3031.
 106. Clinical Trials.gov. Clinical Trials AZDO530 at: http://www.
clinicaltrial.gov/ct2/results?term=AZD0530+ accessed March 2010.
 107. Stratford IJ, Telfer B, Green TP, et al. Inhibition of metastatic 
dissemination following loco-regional control of a primary tumor: 
examining a novel treatment paradigm with the Src kinase inhibitor 
AZD0530 Abstract 4946. AACR 2009.
 108. Boschelli DH, Wu B, Ye F. Synthesis and Src kinase inhibitory 
activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-
7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006;49(26): 
7868–7876.
 109. Rabbani SA, Valentino ML, Ali S, Boschelli F. Inhibitor of Src kinase 
SKI-606 (Bosutinb) blocks prostate cancer growth, invasion and 
experimental skeletal metastases in vitro and in vivo by regulating the 
expression of key intracellular signaling molecules and genes involved 
in prostate cancer progression. Abstract 2325. AACR 2009.
 110. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A 
Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, 
growth, and metastasis in vitro and in vivo.Cancer Res. 2007;67(4): 
1580–1588.
 111. Messersmith WA, Krishnamurthi S, Hewes BA, et al. Bosutinib 
(SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary 
results from a phase 1 study in patients with advanced malignant 
solid tumors. Abstract 3552. 2007 ASCO Annual Meeting. Chicago, 
IL, USA.
 112. Clinical Trials.gov. Clinical Trials Bosutinib at: http://www. 
clinicaltrial.gov/ct2/results?term=Bosutinib+ accessed March 2010.
 113. Roberts WG, Ung E, Whalen P, et al. Antitumor Activity and Pharma-
cology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271. 
Cancer Res. 2008;68(6):1935–1944.
 114. Jayme B, Stokes SJ, Adair JK, et al. Targeting FAK in pancreatic cancer: 
a novel therapeutic approach. Abstract 843, AACR 2209.
 115. Bagi CM, Christensen J, Cohen DP, et al. Sunitinib and PF-562,271 
(FAK/Pyk2 inhibitor) effectively block growth and recovery of human 
hepatocellular carcinoma in a rat xenograft model. Cancer Biology 
and Therapy. 2009;8(9):856–865.
 116. Cascone I, Napione L, Maniero F, Serini G, Bussolino FJ. Stable 
interaction between alpha5beta1 integrin and Tie2 tyrosine kinase 
receptor regulates endothelial cell response to Ang-1. Cell Biol. 
2005;170(6):993–1004.
 117. Bagi CM, Roberts GW, Andresen CJ. Dual focal adhesion kinase/Pyk2 
inhibitor has positive effects on bone tumors: implications for bone 
metastases. Cancer 2008;112(10):2313–2321.
 118. Slack-Davis JK, Martin KH, Tilghman RW, et al. Cellular charac-
terization of a novel focal adhesion kinase inhibitor. J Biol Chem. 
2007;282(20):14845–14852.
 119. Stone RL, Nick AM, Spannuth W, et al. The clinical and biological 
significance of focal adhesion kinase activation in ovarian carcinoma. 
Abstract 3636. AACR 2009.
 120. Dos Santos LA, et al. The FAK Inhibitor PF573228 Demonstrates 
Anti-proliferative and anti-invasive activity in MUC16/CA125 ovarian 
carcinoma cells. Abstract 3519. AACR 2009.
 121. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel 
focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer 
Res. 2007;67(22):10976–10983.
 122. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, 
Hochwald SN. FAK and IGF-IR interact to provide survival sig-
nals in human pancreatic adenocarcinoma cells. Carcinogenesis. 
2008;29(6):1096–1107.
 123. Hao H, Wang Z, Bao X, et al. Dual tyrosine kinase inhibitor for focal 
adhesion kinase and insulin-like growth factor-I receptor (TAE226) 
leads to apoptosis in esophageal cancer by inhibiting AKT-mTOR 
survival signaling. Abstract 1840. AACR 2009.
 124. Ucar D, Kurenova E, Zheng D, et al. A novel small molecule that 
targets the FAK and IGF-1R site of interaction inhibits growth of 
human cancer. Abstract 2008. AACR 2009.
 125. Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L. 
Acquisition of chemoresistance following discontinuous exposures 
to cisplatin is associated in ovarian carcinoma cells with progressive 
alteration of FAK, ERK and p38 activation in response to treatment. 
Gynecol Oncol. 2006;101(3):507–519.
 126. Van Nimwegen MJ, Huigsloot M, Camier A, Tijdens IB, van de 
Water B. Focal adhesion kinase and protein kinase B cooperate 
to suppress doxorubicin-induced apoptosis of breast tumor cells. 
Mol Pharmacol. 2006;70(4):1330–1339.
 127. Kornberg LJ: Adenovirus-mediated transfer of FRNK augments 
drug-induced cytotoxicity in cultured SCCHN cells. Anticancer Res. 
2005;25:4349–4356.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
23
9.
10
8.
7 
on
 0
1-
O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2010:3
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open access 
journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
97
FAK-Src complex as a therapeutic target in cancerDovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
 128. Fang Y, Wang L, Jin J, et al. Ref Focal adhesion kinase affects the 
sensitivity of human hepatocellular carcinoma cell line SMMC-7721 
to TNF- α/cycloheximide-induced apoptosis by regulating protein 
kinase B levels. Eur J Biochem. 2001;268:4513–4519.
 129. Wu ZM, Yuan XH, Jiang PC, et al. Antisens oligonucleodes targeting 
the focal adhesion kinase inhibit proliferation, induce apoptosis and 
cooperate with cytotoxic drugs in human glioma cells. J Neurooncol. 
2006;77:117–123.
 130. Fang Y, Wang L, Jin J, Zha X. Focal adhesion kinase affects the sen-
sitivity of human hepatocellular carcinoma cell line SMMC-7721 to 
TNF-α/cycloheximide-induced apoptosis by regulating protein kinase 
B levels. Eur J Biochem. 2001;268:4513–4519.
 131. Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase target-
ing using in vivo short interfering RNA delivery in neutral liposomes 
for ovarian carcinoma therapy. Clin Cancer Res. 2006;12(16): 
4916–4924.
 132. Smith CS, Golubovskaya VM, Peck E, et al. Effect of focal adhesion 
kinase (FAK) downregulation with FAK antisense oligonucleotides 
and 5-fluorouracil on the viability of melanoma cell lines. Melanoma 
Res. 2005;15(5):357–362.
 133. Somlo G, Atzori F, Strauss L, et al. Dasatinib plus capecitabine 
(Cap) for progressive advanced breast cancer (ABC): Phase I study 
CA180004. Abstract: 1012. 2009 ASCO Annual Meeting, Chicago 
IL, USA.
 134. Teoh D, Ayeni TA, Rubatt JM, et al. In vitrocharacterization of the 
antitumor effects of dasatinib (BMS-354825) in combination with 
paclitaxel and carboplatin in human ovarian cancer cell lines. Abstract 
828. AACR 2009.
 135. Summy JM, Gallick GE. Treatment for advanced tumors: SRC 
reclaims center stage. Clin Cancer Res. 2006;12(5):1398–1401.
 136. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epi-
dermal growth factor receptor and c-Src interactions in human breast 
tumor cells. Mol Carcinog. 1998;21(4):261–272.
 137. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y. Epidermal growth 
factor directs sex-specific steroid signaling through Src activation. J 
Biol Chem. 2007;282(14):10697–10706.
 138. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. 
Mammary tumors expressing the neu proto-oncogene possess 
elevated c-Src tyrosine kinase activity. Mol Cell Biol. 1994;14(1): 
735–743.
 139. Elsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, 
Parsons SJ. Src family kinases and HER2 interactions in human 
breast cancer cell growth and survival. Oncogene. 2001;20(12): 
1465–1475.
 140. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R. Heregulin 
and HER2 signaling selectively activates c-Src phosphorylation at 
tyrosine 215. FEBS Lett. 2003;543(1–3):76–80.
 141. Cabioglu N, Summy J, Miller C, et al. CXCL-12/stromal cell-
derived factor-1alpha transactivates HER2-neu in breast cancer cells 
by a novel pathway involving Src kinase activation. Cancer Res. 
2005;65(15):6493–6497.
 142. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and 
ErbB3 heterocomplex formation and function. Oncogene. 2007;26(24): 
3503–3510.
 143. Song RX, Zhang Z, Santen RJ. Estrogen rapid action via protein 
complex formation involving ERalpha and Src. Trends Endocrinol 
Metab. 2005;16(8):347–353.
 144. Chu I, Arnaout A, Loiseau S, et al. Src promotes estrogen-dependent 
estrogen receptor alpha proteolysis in human breast cancer. J Clin 
Invest. 2007;117(8):2205–2215.
 145. Huang F, Reeves K, Han X, et al. Identification of candidate molecular 
markers predicting sensitivity in solid tumors to dasatinib: rationale 
for patient selection. Cancer Res. 2007;67(5):2226–2238.
 146. Finn RS, Bengala C, Ibrahim N, et al. Phase II Trial of Dasatinib in 
Triple-negative Breast Cancer: Results of Study CA180059. SABCS 
2008.
 147. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of 
epidermal growth factor receptor/c-erbB2 heterodimers mediate an 
autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 
cells. Endocrinology. 2003;144(3):1032–1044.
 148. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, 
Nicholson RI. Tamoxifen resistance in breast cancer cells is accompa-
nied by an enhanced motile and invasive phenotype: inhibition by gefi-
tinib (‘Iressa’, ZD1839). Clin Exp Metastasis. 2004;21(3):201–212.
 149. Nicholson RI, Hutcheson IR, Harper ME, et al. Modulation of epider-
mal growth factor receptor in endocrine-resistant, estrogen-receptor-
positive breast cancer. Ann N Y Acad Sci. 2002;963:104–115.
 150. Massarweh S, Osborne CK, Jiang S, et al. Mechanisms of Tumor 
Regression and Resistance to Estrogen Deprivation and Fulvestrant 
in a Model of Estrogen Receptor-Positive, HER-2/neu-Positive Breast 
Cancer Cancer Res. 2006;66(16):8266–8273.
 151. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen 
resistance: increased estrogen receptor-HER2/neu cross-talk in 
ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96(12): 
926–935.
 152. Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase 
promotes adhesion-independent activation of FAK and enhances cel-
lular migration in tamoxifen-resistant breast cancer cells. Clin Exp 
Metastasis. 2007;24(3):157–167.
 153. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role 
of c-Src and focal adhesion kinase in progression and metastasis 
of estrogen receptor-positive breast cancer. Biochem Biophys Res 
Commun. 2006;341(1):73–81.
 154. Planas-Silva MD, Hamilton KN. Targeting c-Src kinase enhances 
tamoxifen’s inhibitory effect on cell growth by modulating expression 
of cell cycle and survival proteins. Cancer Chemother Pharmacol. 
2007;60(4):535–543.
 155. Planas-Silva MD, Waltz PK. Estrogen promotes reversible epithelial-
to-mesenchymal-like transition and collective motility in MCF-7 
breast cancer cells. J Steroid Biochem Mol Biol. 2007;104(1–2): 
11–21.
 156. Chen Y, Guggisberg N, Jorda M, et al. Combined Src and Aromatase 
Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass 
Pathways Are Activated in AZD0530-Resistant Tumors. Clin Cancer 
Res. 2009;15(10) 3396–3405.
 157. Campbell EJ, McDuff E, Tatarov O, et al. Phosphorylated c-Src in the 
nucleus is associated with improved patient outcome in ER-positive 
breast cancer. Br J Cancer. 2008 Dec 2;99(11):1769–1774.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
23
9.
10
8.
7 
on
 0
1-
O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
